Atorvastatin for Anthracycline-Associated Cardiac Dysfunction

医学 蒽环类 阿托伐他汀 射血分数 内科学 随机对照试验 化疗 队列 回顾性队列研究 心力衰竭 癌症 乳腺癌
作者
Tomas G. Neilan,Thiago Quinaglia,Takeshi Onoue,Syed Mahmood,Zsófia D. Drobni,Hannah Gilman,Amanda M. Smith,Julius C. Heemelaar,Priya Brahmbhatt,Jor Sam Ho,Supraja Sama,Jakub Svoboda,Donna Neuberg,Jeremy S. Abramson,Ephraim P. Hochberg,Jefferey A. Barnes,Philippe Armand,Eric D. Jacobsen,Caron A. Jacobson,Austin I. Kim
出处
期刊:JAMA [American Medical Association]
卷期号:330 (6): 528-528 被引量:84
标识
DOI:10.1001/jama.2023.11887
摘要

Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to anthracycline use. Objective To test whether atorvastatin is associated with a reduction in the proportion of patients with lymphoma receiving anthracyclines who develop cardiac dysfunction. Design, Setting, and Participants Double-blind randomized clinical trial conducted at 9 academic medical centers in the US and Canada among 300 patients with lymphoma who were scheduled to receive anthracycline-based chemotherapy. Enrollment occurred between January 25, 2017, and September 10, 2021, with final follow-up on October 10, 2022. Interventions Participants were randomized to receive atorvastatin, 40 mg/d (n = 150), or placebo (n = 150) for 12 months. Main Outcomes and Measures The primary outcome was the proportion of participants with an absolute decline in left ventricular ejection fraction (LVEF) of ≥10% from prior to chemotherapy to a final value of <55% over 12 months. A secondary outcome was the proportion of participants with an absolute decline in LVEF of ≥5% from prior to chemotherapy to a final value of <55% over 12 months. Results Of the 300 participants randomized (mean age, 50 [SD, 17] years; 142 women [47%]), 286 (95%) completed the trial. Among the entire cohort, the baseline mean LVEF was 63% (SD, 4.6%) and the follow-up LVEF was 58% (SD, 5.7%). Study drug adherence was noted in 91% of participants. At 12-month follow-up, 46 (15%) had a decline in LVEF of 10% or greater from prior to chemotherapy to a final value of less than 55%. The incidence of the primary end point was 9% (13/150) in the atorvastatin group and 22% (33/150) in the placebo group ( P = .002). The odds of a 10% or greater decline in LVEF to a final value of less than 55% after anthracycline treatment was almost 3 times greater for participants randomized to placebo compared with those randomized to atorvastatin (odds ratio, 2.9; 95% CI, 1.4-6.4). Compared with placebo, atorvastatin also reduced the incidence of the secondary end point (13% vs 29%; P = .001). There were 13 adjudicated heart failure events (4%) over 24 months of follow-up. There was no difference in the rates of incident heart failure between study groups (3% with atorvastatin, 6% with placebo; P = .26). The number of serious related adverse events was low and similar between groups. Conclusions and Relevance Among patients with lymphoma treated with anthracycline-based chemotherapy, atorvastatin reduced the incidence of cardiac dysfunction. This finding may support the use of atorvastatin in patients with lymphoma at high risk of cardiac dysfunction due to anthracycline use. Trial Registration ClinicalTrials.gov Identifier: NCT02943590
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
啦啦啦发布了新的文献求助30
刚刚
刚刚
希望天下0贩的0应助张博采纳,获得10
刚刚
11发布了新的文献求助10
1秒前
2秒前
2秒前
坨坨发布了新的文献求助10
5秒前
虚幻蜗牛完成签到,获得积分10
6秒前
小桔子发布了新的文献求助10
6秒前
王海丽完成签到,获得积分10
6秒前
xiaofeiyan发布了新的文献求助20
7秒前
7秒前
酷酷的泥猴桃完成签到,获得积分10
8秒前
9秒前
11秒前
Georges-09完成签到,获得积分10
11秒前
12秒前
慕青应助ddfighting采纳,获得10
12秒前
坚果发布了新的文献求助10
12秒前
汉堡包应助美丽的颜演采纳,获得10
12秒前
ll应助拍不醒的薄荷采纳,获得10
12秒前
13秒前
完美世界应助baoziya采纳,获得10
13秒前
14秒前
14秒前
hdy331完成签到,获得积分10
15秒前
15秒前
axin发布了新的文献求助10
16秒前
量子星尘发布了新的文献求助10
16秒前
万俟完成签到 ,获得积分10
17秒前
小王同学发布了新的文献求助10
17秒前
19秒前
Coraline应助柳七采纳,获得10
19秒前
smalldesk发布了新的文献求助10
19秒前
慢慢学习的小白完成签到,获得积分20
19秒前
壮观鞋垫发布了新的文献求助10
20秒前
20秒前
lzr关注了科研通微信公众号
21秒前
共享精神应助顺利的荔枝采纳,获得10
21秒前
小朱完成签到,获得积分10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971441
求助须知:如何正确求助?哪些是违规求助? 3516161
关于积分的说明 11181180
捐赠科研通 3251322
什么是DOI,文献DOI怎么找? 1795788
邀请新用户注册赠送积分活动 876026
科研通“疑难数据库(出版商)”最低求助积分说明 805228